瑞士Pevion Biotech Ltd www.pevion.com
Pevion生物技术公司是一家私人拥有的瑞士生物制药公司，把重点放在发展预防性和治疗性疫苗的基础上的市场验证， fluvirus的virosome技术。 Virosomes小球形囊泡含有病毒膜蛋白（融合蛋白的流感病毒）中嵌入脂膜。它们可装载几乎与任何抗原的选择。 Pevion生物技术的发展管道除其他外，包括疫苗候选人对乳腺癌，念珠菌，呼吸道合胞病毒，疟疾和丙型肝炎病毒。该公司2003年开始作为一家合资公司的巴赫姆控股公司和生物技术公司的贝尔纳，现在Crucell NV公司。
Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the development of prophylactic and therapeutic vaccines based on a market-validated, fluvirus-based virosome-technology. Virosomes are small spherical vesicles containing viral membrane proteins (fusion proteins of the influenza virus) embedded in lipid membranes. They can be loaded with almost any antigen of choice. Pevion Biotech’s development pipeline includes, among others, vaccines candidates against breast cancer, Candida, RSV, malaria and HCV. The company started in 2003 as a joint venture company of Bachem Holding AG and of Berna Biotech AG, now Crucell NV. 
 Pevion Biotech successfully applies its proprietary virosome-based technology platforms to the development of efficient and safe prophylactic/therapeutic vaccines. Additionally, Pevion Biotech gives access to these platforms (PeviPROTM and PeviTERTM). Pevion Biotech is located in Bern, Switzerland and has 22 employees.
Pevion Biotech´s high qualified scientists and development personnel are specialized in bringing novel vaccines from research into clinical development.
Pevion Biotech´s virosomes are already market approved and can be manufactured on a large scale under GMP.
Pevion Biotech´s technology can be adapted to meet the various requirements of a state-of-the-art-carrier system.
Pevion Biotech is a partner in vaccine formulation to pharmaceutical companies and research institutions.